产品
编 号：F225240
分子式：C27H27F3N2O4S
分子量：532.57
分子式：C27H27F3N2O4S
分子量：532.57
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1809068-70-9
产品详情
生物活性：
SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activity.
体内研究：
SMAP-2 significantly reduces abdominal aortic aneurysms (AAA) incidence and aortic dilation in pro-AAA apolipoprotein E-null (ApoE-/-) mice.SMAP-2 (15 mg/kg; i.g.; daily; 6 days a week; for approximately 14 days) has anti-tumor activity in pancreatic cancer mice model.Animal Model:NSG mice, with PANC89 cells xenograft
Dosage:15 mg/kg
Administration:Oral gavage, daily, 6 days a week, for approximately 14 days
Result:Decreased tumor growth and tumor weight.
体外研究：
SMAP-2 reduces cell viability of pancreatic ductal adenocarcinoma (PDA) cell lines in a dose-dependent manner.
SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activity.
体内研究：
SMAP-2 significantly reduces abdominal aortic aneurysms (AAA) incidence and aortic dilation in pro-AAA apolipoprotein E-null (ApoE-/-) mice.SMAP-2 (15 mg/kg; i.g.; daily; 6 days a week; for approximately 14 days) has anti-tumor activity in pancreatic cancer mice model.Animal Model:NSG mice, with PANC89 cells xenograft
Dosage:15 mg/kg
Administration:Oral gavage, daily, 6 days a week, for approximately 14 days
Result:Decreased tumor growth and tumor weight.
体外研究：
SMAP-2 reduces cell viability of pancreatic ductal adenocarcinoma (PDA) cell lines in a dose-dependent manner.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备